February 2013- Volume 9, Issue 2

February 2013

In this Issue

Feature

SOT 2013 Annual Meeting and ToxExpo: One-stop toxicology shop (Part 2)

SOT 2013 Annual Meeting and ToxExpo: One-stop toxicology shop (Part 2)

Annual meeting of the Society of Toxicology promises a wide range of toxicology and safety assessment science

SOT 2013 Annual Meeting and ToxExpo: One-stop toxicology shop (Part 1)

SOT 2013 Annual Meeting and ToxExpo: One-stop toxicology shop (Part 1)

Annual meeting of the Society of Toxicology promises a wide range of toxicology and safety assessment science

Commentary

The times, they are a changin’ in the biopharma market

The times, they are a changin’ in the biopharma market

The biopharmaceutical development community has successfully developed a broad range of highly effective therapies for a wide variety of serious and debilitating diseases. However, developing biopharmaceuticals is inherently an extremely challenging and commercially risky undertaking, often working to tight timelines and typically resource- constrained.

That’s not fair! Or is it?

That’s not fair! Or is it?

Fair deserves a rest. A more precise set of words could include meritorious, disciplined and ethical.

Editor's Focus

Sherley v. Sebelius: Where do we go from here?

Sherley v. Sebelius: Where do we go from here?

“What we have going on right now with hESC research is the civil rights movement of the 21st century, a debate on whether science is going to enslave and manipulate the embryo,” says Samuel Casey, managing director and general counsel for the Law of Life Project, the law firm that represented the plaintiffs in Sherley v. Sebelius. “They are the new slaves. They are too small to vote. We are reopening the door on human subject experimentation, something that until now, only World War II closed the door on. I have spent the last 10 years trying to point out the truth, and this is where we today.”

Diagnostics

Life Tech, Boston Children’s Hospital launch clinical genomics company

Life Tech, Boston Children’s Hospital launch clinical genomics company

Life Technologies Corp. and Boston Children’s Hospital announced in early January the launch of Claritas Genomics, a new company formed to develop next-generation, genetic and genomics-based diagnostic testing solutions

Lilly, Dako make powerful companions

Lilly, Dako make powerful companions

Collaboration on companion diagnostics will help speed oncology products to market

CDx deal is thrice as nice

CDx deal is thrice as nice

Already partnered on the development of a companion diagnostic test for lymphoma, Eisai and Epizyme bring Roche Molecular Diagnostics into the fold

QIAGEN plus four

QIAGEN plus four

Company’s agreements with four companies boost its diagnostic pipeline for personalized healthcare applications

Looking for a prenatal payoff

Looking for a prenatal payoff

Illumina agrees to acquire Verinata Health for $350 million upfront plus $100 million in potential milestones

Omics & Systems Biology

Shire acquires Lotus Tissue Repair, gains potential therapy for rare skin disease

Shire acquires Lotus Tissue Repair, gains potential therapy for rare skin disease

Acquisition consists of an undisclosed upfront payment as well as certain additional payments if specified safety and development milestones are met

My antisense is tingling

My antisense is tingling

Strategic alliance between AstraZeneca and Isis aims to develop next-generation RNA therapeutics

From platform to clinic

From platform to clinic

Partnership between Heptares Therapeutics and Cubist Pharmaceuticals targets GCPRs for unmet needs in acute care

Autism spectrum under study

Autism spectrum under study

Population Dx, Toronto’s Hospital for Sick Children discover gene variants for autism spectrum disorder

MD Anderson, Trovagene to study transrenal BRAF mutations in primary, metastatic cancers

MD Anderson, Trovagene to study transrenal BRAF mutations in primary, metastatic cancers

The University of Texas MD Anderson Cancer Center and Trovagene Inc., a developer of transrenal molecular diagnostics, have entered into a clinical collaboration with to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers

Research & Development

A LEAP forward for stem cell research

A LEAP forward for stem cell research

Collaboration will give world-class scientific team access to cutting-edge private technologies

Stem cell developers Give Cures

Stem cell developers Give Cures

CET, John Paul II Medical Research Institute to develop stem cell biobank for academia, government, industry

Neuroscience focus of AstraZeneca, Vanderbilt deal

Neuroscience focus of AstraZeneca, Vanderbilt deal

Vanderbilt University has joined forces with AstraZeneca PLC in a research deal to identify potential treatments for psychosis and other psychiatric symptoms associated with diseases such as Alzheimer’s and schizophrenia

End of the road for hESC opponents

End of the road for hESC opponents

U.S. Supreme Court declines to hear case seeking to restrict federal funding for human embryonic stem cell research

Tools & Technology

Alliance of a lifetime

Alliance of a lifetime

Almac and TTP Labtech partner on fluorescence lifetime technology for screening applications

Market share for Bio-Rad; focused direction for MorphoSys

Market share for Bio-Rad; focused direction for MorphoSys

Bio-Rad acquires MorphoSys’ AbD Serotec for approximately $70 million in a cash deal

124 and counting

124 and counting

Venerable WHEATON Industries acquires chromatography vial supply company MicroLiter Analytical Supplies

Shifting from manual to automatic

Shifting from manual to automatic

Roche, PSS unite to develop fully automated emulsion PCR instrument

Global News

Getting under our skin

Getting under our skin

Pfizer, Halozyme partner on subcutaneous biologics delivery in potential $500 million-plus deal

Improving immune response

Improving immune response

German pharma Phenex joins forces with Janssen Biotech to target autoimmune, chronic inflammatory disorders

Trio tackles translational research

Trio tackles translational research

Three-way collaboration tackles Parkinson’s disease

Getting AMP-ed up

Getting AMP-ed up

Daiichi Sankyo, Amplimmune partner to develop immune modulation therapy

Aligned in oncology

Aligned in oncology

Chugai and Debiopharm announce an exclusive license agreement for anti-cancer agent FF284

Contract Services

Controlling the flow of information

Controlling the flow of information

PAREXEL acquires regulatory information management provider Liquent

A deal with 'significant efficiencies'

A deal with 'significant efficiencies'

CNS acquires business assets of long-time partner BELTAS

Second time around

Second time around

LGC acquires bioanalytical sciences business from Quotient Bioresearch

Not your usual CRO arrangement

Not your usual CRO arrangement

U.S.-based biopharma Onconova partners with Indian CRO GVK Biosciences on development of cancer drugs

Questcor Pharmaceuticals acquires BioVectra

Questcor Pharmaceuticals acquires BioVectra

Questcor Pharmaceuticals Inc. has signed a definitive agreement to acquire all issued and outstanding shares of BioVectra Inc., for an upfront payment of nearly $50 million
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN June 2022 magazine issue front cover

Latest Issue  

• Volume 18 • Issue 6 • June 2022

June 2022

June 2022 Issue